Nanostring Technologies Inc Revenue Growth Rates (NSTG), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Nanostring Technologies Inc   (NASDAQ: NSTG)
 

NSTG's Revenue Growth by Quarter and Year

Nanostring Technologies Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NSTG Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December -
3rd Quarter September 48.09
2nd Quarter June 44.16
1st Quarter March 35.81
FY 128.06

NSTGs Annual Revenue
Nanostring Technologies Inc 's Revenue in the fiscal year 2022 $ 127.26 millions
Nanostring Technologies Inc 's Revenue in the fiscal year 2021 $ 145.09 millions
Nanostring Technologies Inc 's Revenue in the fiscal year 2020 $ 117.32 millions
Nanostring Technologies Inc 's Revenue in the fiscal year 2019 $ 125.57 millions
Nanostring Technologies Inc 's Revenue in the fiscal year 2018 $ 106.73 millions




NSTG Revenue third quarter 2023 Y/Y Growth Comment
Nanostring Technologies Inc achieved in the third quarter 2023, above Company average Revenue rise of 62.79% year on year, to $ 48.09 millions.

Looking into third quarter 2023 results within Biotechnology & Pharmaceuticals industry 15 other companies have achieved higher Revenue growth. While Nanostring Technologies Inc ' s Revenue jump of 62.79% ranks overall at the positon no. 293 in the third quarter 2023.


NSTG Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December - -18.94 % 17.1 % -1.81 %
3rd Quarter September 62.79 % -20.48 % 16.64 % 4.08 %
2nd Quarter June 37.06 % -4.84 % 49.82 % -25.54 %
1st Quarter March 15.22 % -1.71 % 18.83 % -3.9 %
FY   - -12.29 % 23.67 % -

Financial Statements
Nanostring Technologies Inc 's third quarter 2023 Revenue $ 48.09 millions NSTG's Income Statement
Nanostring Technologies Inc 's third quarter 2022 Revenue $ 29.54 millions Quarterly NSTG's Income Statement


NSTG Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - 16.52 % 14.29 % 13.85 %
3rd Quarter September 8.9 % -8.32 % 9.72 % 40.93 %
2nd Quarter June 23.32 % 3.67 % 7.08 % -15.07 %
1st Quarter March 4.04 % -26.8 % -12.8 % -27.94 %
FY (Year on Year)   - -12.29 % 23.67 % -


Back to NSTG Growth rate Comparisons >> Back to NSTG Growth rate Comparisons >>


Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #16
Healthcare Sector #113
Overall #293

Revenue Y/Y Growth Statistics
High Average Low
81.88 % 21.31 % -34.56 %
(Dec 31 2017)   (Dec 31 2018)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #16
Healthcare Sector #113
Overall #293
Revenue Y/Y Growth Statistics
High Average Low
81.88 % 21.31 % -34.56 %
(Dec 31 2017)   (Dec 31 2018)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Nanostring Technologies Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
69.87 % 7.25 % -49.7 %
(Dec 31 2017)  


NSTG's III. Quarter Q/Q Revenue Comment
Nanostring Technologies Inc achieved in the III. Quarter 2023 above company average sequential Revenue increase of 8.9%, to $ 48.09 millions, from $44.16 millions in the second quarter.

Within Biotechnology & Pharmaceuticals industry 42 other companies have achieved higher Revenue quarter on quarter growth. While Nanostring Technologies Inc 's Revenue growth quarter on quarter, overall rank is 875.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #43
Healthcare Sector #207
Overall #875
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #43
Healthcare Sector #207
Overall #875
Revenue Q/Q Growth Statistics
High Average Low
69.87 % 7.25 % -49.7 %
(Dec 31 2017)  


NSTG's III. Quarter Q/Q Revenue Comment
Nanostring Technologies Inc achieved in the III. Quarter 2023 above company average sequential Revenue increase of 8.9%, to $ 48.09 millions, from $44.16 millions in the second quarter.

Within Biotechnology & Pharmaceuticals industry 42 other companies have achieved higher Revenue quarter on quarter growth. While Nanostring Technologies Inc 's Revenue growth quarter on quarter, overall rank is 875.


Nanostring Technologies Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)
Cumulative Revenue 12 Months Ending $ 162.47 $ 143.92 $ 131.99 $ 127.26 $ 135.30
Y / Y Revenue Growth (TTM) 20.09 % 0.71 % -8.69 % -12.28 % -2.59 %
Year on Year Revenue Growth Overall Ranking # 2187 # 786 # 170 # 942 # 1352
Seqeuential Revenue Change (TTM) 12.89 % 9.04 % 3.71 % -5.94 % -5.32 %
Seq. Revenue Growth (TTM) Overall Ranking # 2606 # 2452 # 761 # 2049 # 1244


Cumulative Revenue growth Comment
Nanostring Technologies Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 20.09% year on year, to $ 162 millions if the fiscal year would have ended in Sep 30 2023.
Nanostring Technologies Inc 's trailing twelve months Revenue growth was higher than company's average 13.65% and higher than 0.71% growth in Jun 30 2023.
But from twelve months ended Jun 30 2023 rise was beneth at 12.89 % from $143.92 millions achieved in the period from Jun 30 2023 to Sep 30 2022.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at13.65%.
The momentum is even more impressive from twelve months ended Jun 30 2023 exhibited at 12.89 % increase from $143.92 millions in the period from Jun 30 2023 to Sep 30 2022.

In the Healthcare sector 354 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 786 to 2187.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 38
Healthcare Sector # 355
Overall # 2187

Revenue TTM Y/Y Growth Statistics
High Average Low
43.16 %
 13.65 %
-14.99 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 38
Sector # 412
S&P 500 # 2606
Cumulative Revenue growth Comment
Nanostring Technologies Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 20.09% year on year, to $ 162 millions if the fiscal year would have ended in Sep 30 2023.
Nanostring Technologies Inc 's trailing twelve months Revenue growth was higher than company's average 13.65% and higher than 0.71% growth in Jun 30 2023.
But from twelve months ended Jun 30 2023 rise was beneth at 12.89 % from $143.92 millions achieved in the period from Jun 30 2023 to Sep 30 2022.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at13.65%.
The momentum is even more impressive from twelve months ended Jun 30 2023 exhibited at 12.89 % increase from $143.92 millions in the period from Jun 30 2023 to Sep 30 2022.

In the Healthcare sector 354 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 786 to 2187.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 38
Healthcare Sector # 355
Overall # 2187

Revenue TTM Y/Y Growth Statistics
High Average Low
43.16 %
13.65 %
-14.99 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 38
Sector # 412
S&P 500 # 2606




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NSTG's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2023
Reflect Scientific Inc107.66%$ 107.664 millions
Agile Therapeutics Inc106.03%$ 106.029 millions
Precipio inc 103.97%$ 103.973 millions
Beone Medicines Ltd 101.56%$ 101.561 millions
Eton Pharmaceuticals Inc 98.91%$ 98.913 millions
Northwest Biotherapeutics Inc97.09%$ 97.087 millions
Revance Therapeutics Inc 95.68%$ 95.678 millions
Evoke Pharma Inc 87.82%$ 87.821 millions
Quantum Cyber N v 87.69%$ 87.692 millions
Xoma Royalty Corporation84.04%$ 84.035 millions
Proqr Therapeutics N v 82.00%$ 81.997 millions
Catalyst Pharmaceuticals Inc 79.39%$ 79.386 millions
Esperion Therapeutics Inc 78.97%$ 78.973 millions
Docgo Inc 78.83%$ 78.828 millions
Precision Biosciences Inc78.19%$ 78.188 millions
Marpai Inc76.77%$ 76.771 millions
Bicycle Therapeutics Plc76.05%$ 76.053 millions
Intra cellular Therapies Inc 75.56%$ 75.557 millions
Agilon Health Inc 74.95%$ 74.951 millions
Rxsight Inc 72.26%$ 72.263 millions
Elite Pharmaceuticals Inc 71.86%$ 71.860 millions
Procept Biorobotics Corporation71.38%$ 71.379 millions
Pacific Biosciences Of California Inc 69.92%$ 69.917 millions
Biocardia Inc 68.40%$ 68.396 millions
Xtant Medical Holdings Inc 68.26%$ 68.262 millions
Cvrx inc 67.98%$ 67.978 millions
Merus N v 67.65%$ 67.649 millions
Alimera Sciences Inc66.25%$ 66.245 millions
Castle Biosciences Inc 66.15%$ 66.148 millions
Coherus Oncology inc 64.16%$ 64.160 millions


About Nanostring Technologies Inc Revenue Growth Rates (NSTG), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Nanostring Technologies Inc (CIK 1401708).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001401708-23-000235
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Nanostring Technologies Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.